Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
3599 | 1947 | 47.1 | 88% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
419 | 3 | ADENOVIRUS//MERKEL CELL CARCINOMA//GENE THERAPY | 28518 |
564 | 2 | GENE THERAPY//ADENOVIRUS//HUMAN GENE THERAPY | 14456 |
3599 | 1 | ADENOVIRUS//COXSACKIE ADENOVIRUS RECEPTOR//HUMAN GENE THER Y | 1947 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ADENOVIRUS | authKW | 592797 | 22% | 9% | 437 |
2 | COXSACKIE ADENOVIRUS RECEPTOR | authKW | 466681 | 2% | 80% | 37 |
3 | HUMAN GENE THER Y | address | 391828 | 7% | 19% | 130 |
4 | GENE TRANSFER REGULAT | address | 346813 | 2% | 54% | 41 |
5 | COXSACKIE AND ADENOVIRUS RECEPTOR | authKW | 303589 | 1% | 88% | 22 |
6 | VIROL PATHOGENESE VIRALE | address | 217722 | 1% | 73% | 19 |
7 | ADENOVIRUS VECTOR | authKW | 212028 | 4% | 16% | 85 |
8 | COXSACKIEVIRUS AND ADENOVIRUS RECEPTOR | authKW | 188687 | 1% | 63% | 19 |
9 | PENTON BASE | authKW | 176410 | 1% | 75% | 15 |
10 | HEXON | authKW | 158438 | 1% | 42% | 24 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Virology | 32798 | 31% | 0% | 609 |
2 | Medicine, Research & Experimental | 10755 | 28% | 0% | 548 |
3 | Biotechnology & Applied Microbiology | 8924 | 29% | 0% | 569 |
4 | Genetics & Heredity | 6289 | 24% | 0% | 474 |
5 | Oncology | 816 | 12% | 0% | 243 |
6 | Biochemistry & Molecular Biology | 728 | 20% | 0% | 387 |
7 | Cell Biology | 233 | 8% | 0% | 149 |
8 | Materials Science, Biomaterials | 68 | 1% | 0% | 24 |
9 | Pharmacology & Pharmacy | 63 | 6% | 0% | 119 |
10 | Biochemical Research Methods | 46 | 3% | 0% | 51 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | HUMAN GENE THER Y | 391828 | 7% | 19% | 130 |
2 | GENE TRANSFER REGULAT | 346813 | 2% | 54% | 41 |
3 | VIROL PATHOGENESE VIRALE | 217722 | 1% | 73% | 19 |
4 | GENE THER Y | 157011 | 8% | 6% | 164 |
5 | TRANSLAT IMMUNOVIROL PROGRAM | 120623 | 1% | 77% | 10 |
6 | STENA 1B | 70564 | 0% | 75% | 6 |
7 | TRANSLAT IMMUNOVIROL BIODEF PROGRAM | 52813 | 0% | 42% | 8 |
8 | BIOTECHNOL THER EUT | 50328 | 1% | 19% | 17 |
9 | THER EUT GENE MODULAT | 49058 | 1% | 24% | 13 |
10 | VIROL GENE THER Y PROGRAM | 48017 | 0% | 44% | 7 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | GENE THERAPY | 64541 | 7% | 3% | 127 |
2 | HUMAN GENE THERAPY | 59967 | 6% | 3% | 113 |
3 | JOURNAL OF VIROLOGY | 30712 | 14% | 1% | 279 |
4 | MOLECULAR THERAPY | 29660 | 4% | 2% | 82 |
5 | JOURNAL OF GENE MEDICINE | 23545 | 2% | 3% | 46 |
6 | CANCER GENE THERAPY | 23273 | 3% | 3% | 54 |
7 | VIROLOGY | 9367 | 5% | 1% | 106 |
8 | CURRENT GENE THERAPY | 2842 | 1% | 2% | 10 |
9 | JOURNAL OF CONTROLLED RELEASE | 2676 | 2% | 0% | 36 |
10 | JOURNAL OF GENERAL VIROLOGY | 2412 | 2% | 0% | 46 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ADENOVIRUS | 592797 | 22% | 9% | 437 | Search ADENOVIRUS | Search ADENOVIRUS |
2 | COXSACKIE ADENOVIRUS RECEPTOR | 466681 | 2% | 80% | 37 | Search COXSACKIE+ADENOVIRUS+RECEPTOR | Search COXSACKIE+ADENOVIRUS+RECEPTOR |
3 | COXSACKIE AND ADENOVIRUS RECEPTOR | 303589 | 1% | 88% | 22 | Search COXSACKIE+AND+ADENOVIRUS+RECEPTOR | Search COXSACKIE+AND+ADENOVIRUS+RECEPTOR |
4 | ADENOVIRUS VECTOR | 212028 | 4% | 16% | 85 | Search ADENOVIRUS+VECTOR | Search ADENOVIRUS+VECTOR |
5 | COXSACKIEVIRUS AND ADENOVIRUS RECEPTOR | 188687 | 1% | 63% | 19 | Search COXSACKIEVIRUS+AND+ADENOVIRUS+RECEPTOR | Search COXSACKIEVIRUS+AND+ADENOVIRUS+RECEPTOR |
6 | PENTON BASE | 176410 | 1% | 75% | 15 | Search PENTON+BASE | Search PENTON+BASE |
7 | HEXON | 158438 | 1% | 42% | 24 | Search HEXON | Search HEXON |
8 | PROTEIN IX | 142558 | 1% | 91% | 10 | Search PROTEIN+IX | Search PROTEIN+IX |
9 | RETARGETING | 139694 | 2% | 30% | 30 | Search RETARGETING | Search RETARGETING |
10 | CAR | 125586 | 3% | 12% | 67 | Search CAR | Search CAR |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | COUGHLAN, L , ALBA, R , PARKER, AL , BRADSHAW, AC , MCNEISH, IA , NICKLIN, SA , BAKER, AH , (2010) TROPISM-MODIFICATION STRATEGIES FOR TARGETED GENE DELIVERY USING ADENOVIRAL VECTORS.VIRUSES-BASEL. VOL. 2. ISSUE 10. P. 2290 -2355 | 275 | 75% | 34 |
2 | SHARMA, A , LI, XX , BANGARI, DS , MITTAL, SK , (2009) ADENOVIRUS RECEPTORS AND THEIR IMPLICATIONS IN GENE DELIVERY.VIRUS RESEARCH. VOL. 143. ISSUE 2. P. 184-194 | 137 | 79% | 40 |
3 | CAMPOS, SK , BARRY, MA , (2007) CURRENT ADVANCES AND FUTURE CHALLENGES IN ADENOVIRAL VECTOR BIOLOGY AND TARGETING.CURRENT GENE THERAPY. VOL. 7. ISSUE 3. P. 189-204 | 129 | 78% | 103 |
4 | SMITH, JG , WIETHOFF, CM , STEWART, PL , NEMEROW, GR , (2010) ADENOVIRUS.CELL ENTRY BY NON-ENVELOPED VIRUSES. VOL. 343. ISSUE . P. 195 -224 | 114 | 79% | 36 |
5 | BEATTY, MS , CURIEL, DT , (2012) ADENOVIRUS STRATEGIES FOR TISSUE-SPECIFIC TARGETING.APPLICATIONS OF VIRUSES FOR CANCER THERAPY. VOL. 115. ISSUE . P. 39 -67 | 106 | 83% | 11 |
6 | MIZUGUCHI, H , HAYAKAWA, T , (2004) TARGETED ADENOVIRUS VECTORS.HUMAN GENE THERAPY. VOL. 15. ISSUE 11. P. 1034-1044 | 98 | 91% | 125 |
7 | HALL, K , ZAJDEL, MEB , BLAIR, GE , (2010) UNITY AND DIVERSITY IN THE HUMAN ADENOVIRUSES: EXPLOITING ALTERNATIVE ENTRY PATHWAYS FOR GENE THERAPY.BIOCHEMICAL JOURNAL. VOL. 431. ISSUE . P. 321 -336 | 125 | 68% | 16 |
8 | UUSI-KERTTULA, H , HULIN-CURTIS, S , DAVIES, J , PARKER, AL , (2015) ONCOLYTIC ADENOVIRUS: STRATEGIES AND INSIGHTS FOR VECTOR DESIGN AND IMMUNO-ONCOLYTIC APPLICATIONS.VIRUSES-BASEL. VOL. 7. ISSUE 11. P. 6009 -6042 | 118 | 60% | 5 |
9 | RUSSELL, WC , (2009) ADENOVIRUSES: UPDATE ON STRUCTURE AND FUNCTION.JOURNAL OF GENERAL VIROLOGY. VOL. 90. ISSUE . P. 1 -20 | 122 | 56% | 112 |
10 | BARNETT, BG , CREWS, CJ , DOUGLAS, JT , (2002) TARGETED ADENOVIRAL VECTORS.BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION. VOL. 1575. ISSUE 1-3. P. 1-14 | 116 | 76% | 125 |
Classes with closest relation at Level 1 |